ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
126.526,27
1,51%
S&P 500
5.099,96
1,02%
US Dollar vs BRL
5,1163
0,00%
Bitcoin
63.532,41
0,19%
Brent Oil
88,165
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Notícias

ALNY Alnylam Pharmaceuticals Inc

143,31
-0,40 (-0,28%)
26 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Alnylam Pharmaceuticals Inc ALNY NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
-0,40 -0,28% 143,31 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
144,08 143,00 146,065 143,31 143,71
mais cotações »

Notícias Recentes

Data Hora Fonte Título
18/04/202409:00BWAlnylam to Webcast Conference Call Discussing First Quarter..
07/04/202409:00BWAlnylam Presents Positive Results from the KARDIA-2 Phase 2..
20/03/202409:00BWAlnylam to Webcast Investor Event to Discuss Results from..
13/03/202408:30BWAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis..
06/03/202408:50BWAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse,..
05/03/202419:39BWAlnylam annonce des résultats positifs de l’étude KARDIA-2..
05/03/202409:30BWAlnylam Reports Positive KARDIA-2 Topline Study Results..
27/02/202410:30BWAlnylam to Webcast Presentations at Upcoming March Investor..
15/02/202410:00BWAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year..
29/01/202410:00BWAlnylam to Webcast Conference Call Discussing Fourth Quarter..
09/01/202410:05BWAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year..
07/01/202420:00BWAlnylam Announces Preliminary* Fourth Quarter and Full Year..
02/01/202409:30BWAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan..
13/12/202309:30BWAlnylam Highlights Significant Progress with Platform..
06/12/202310:00BWAlnylam to Webcast Virtual R&D Day
30/11/202310:00BWAlnylam Ranks #1 on Boston Globe’s Top Places to Work List..
12/11/202314:08BWAlnylam présente des résultats positifs de l'étude KARDIA-1..
11/11/202318:00BWAlnylam Presents Positive Results from the KARDIA-1 Phase 2..
07/11/202310:00BWAlnylam to Webcast Presentations at Upcoming November..
02/11/202309:00BWAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial..
26/10/202315:00BWAlnylam Recognized by Science Magazine as Top Employer for..
25/10/202318:19BWAlnylam Announces Publication of Results from APOLLO-B Phase..
25/10/202312:05BWAlnylam Reports Additional Positive Interim Phase 1 Results..
19/10/202309:00BWAlnylam to Webcast Conference Call Discussing Third Quarter..
10/10/202308:02IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
09/10/202309:23DJNAlnylam Ending Onpattro ATTR-CM Pursuit After FDA Rejection
09/10/202308:30BWAlnylam Announces Receipt of Complete Response Letter from..
06/10/202308:00BWAlnylam to Present Additional Data for Patisiran in Patients..
13/09/202318:48DJNAlnylam Pharmaceuticals Says FDA Panel Votes in Favor of..
13/09/202317:57BWAlnylam Announces Positive Outcome of FDA Advisory Committee..
13/09/202308:00BWAlnylam Stock Trading Halted Today; FDA Advisory Committee..
07/09/202308:00BWAlnylam Reports Positive Topline Results from KARDIA-1 Phase..
06/09/202312:46BWÉlaboration par un groupe international de défenseurs des..
06/09/202311:45BWErstes Empfehlungspaket für die ganzheitliche Betreuung von..
06/09/202304:00BWFirst Set of Recommendations Advocating for the Holistic..
25/08/202318:00BWAlnylam to Appeal Claim Construction Ruling on Two Patents..
03/08/202309:00BWAlnylam Pharmaceuticals Reports Second Quarter 2023..
02/08/202309:30BWAlnylam to Webcast Presentation at Canaccord Genuity 43rd..
24/07/202316:43BWAlnylam gibt Partnerschaft mit Roche zur gemeinsamen..
24/07/202310:11BWAlnylam annonce un partenariat avec Roche pour co-développer..
24/07/202302:00BWAlnylam Announces Partnership with Roche to Co-Develop and..
21/07/202319:21BWアルナイラムによるジレベシランの第1相試験結果がニューイングランド医学誌に掲載
20/07/202309:00BWAlnylam to Webcast Conference Call Discussing Second Quarter..
20/07/202307:42BWAlnylam veröffentlicht Ergebnisse der Phase-1-Studie für..
19/07/202318:00BWAlnylam Announces Publication of Phase 1 Study Results for..
17/07/202303:21BWAlnylam Reports Updated Positive Interim Phase 1 Results for..
30/06/202310:00BWAlnylam Announces Date of Planned FDA Advisory Committee..
05/06/202317:00BWAlnylam to Webcast Presentation at Goldman Sachs 44th Annual..
20/05/202311:50BWAlnylam Presents 18-Month Results from the APOLLO-B Phase 3..
04/05/202309:00BWAlnylam Pharmaceuticals Reports First Quarter 2023 Financial..

Seu Histórico Recente

NASDAQ
ALNY
Alnylam Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados